Aldesleukin Completed Phase 1 Trials for Metastatic Melanoma / Renal Cell Adenocarcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00304460Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer